The multistep process of TP53 mutation expansion during myeloproliferative neoplasm (MPN) transformation into acute myeloid leukemia (AML) has been documented retrospectively. It is currently unknown how common TP53 mutations with low variant allele frequency (VAF) are, whether they are linked to hydroxyurea (HU) cytoreduction, and what disease progression risk they carry. Using ultra-deep next-generation sequencing, we examined 254 MPN patients treated with HU, interferon alpha-2a or anagrelide and 85 untreated patients. We found TP53 mutations in 50 cases (0.2-16.3% VAF), regardless of disease subtype, driver gene status and cytoreduction. Both therapy and TP53 mutations were strongly associated with older age. Over-time analysis showed that the mutations may be undetectable at diagnosis and slowly increase during disease course. Although three patients with TP53 mutations progressed to TP53-mutated or TP53-wild-type AML, we did not observe a significant age-independent impact on overall survival during the follow-up. Further, we showed that complete p53 inactivation alone led to neither blast transformation nor HU resistance. Altogether, we revealed patient's age as the strongest factor affecting low-burden TP53 mutation incidence in MPN and found no significant age-independent association between TP53 mutations and hydroxyurea. Mutations may persist at low levels for years without an immediate risk of progression.

CeMM Research Center for Molecular Medicine of Austrian Academy of Sciences Vienna Austria

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Clinical Hematology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine 1 Division of Hematology and Blood Coagulation Medical University of Vienna Austria

Department of Internal Medicine Hematology and Oncology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology Faculty of Medicine Masaryk University Brno Czech Republic Central European Institute of Technology Masaryk University Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc19013115

003      

CZ-PrNML

005      

20240117091009.0

007      

ta

008      

190405s2018 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1038/leu.2017.230 $2 doi

035    __

$a (PubMed)28744014

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Kubesova, B $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic.

245    10

$a Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status / $c B. Kubesova, S. Pavlova, J. Malcikova, J. Kabathova, L. Radova, N. Tom, B. Tichy, K. Plevova, B. Kantorova, K. Fiedorova, M. Slavikova, V. Bystry, J. Kissova, B. Gisslinger, H. Gisslinger, M. Penka, J. Mayer, R. Kralovics, S. Pospisilova, M. Doubek,

520    9_

$a The multistep process of TP53 mutation expansion during myeloproliferative neoplasm (MPN) transformation into acute myeloid leukemia (AML) has been documented retrospectively. It is currently unknown how common TP53 mutations with low variant allele frequency (VAF) are, whether they are linked to hydroxyurea (HU) cytoreduction, and what disease progression risk they carry. Using ultra-deep next-generation sequencing, we examined 254 MPN patients treated with HU, interferon alpha-2a or anagrelide and 85 untreated patients. We found TP53 mutations in 50 cases (0.2-16.3% VAF), regardless of disease subtype, driver gene status and cytoreduction. Both therapy and TP53 mutations were strongly associated with older age. Over-time analysis showed that the mutations may be undetectable at diagnosis and slowly increase during disease course. Although three patients with TP53 mutations progressed to TP53-mutated or TP53-wild-type AML, we did not observe a significant age-independent impact on overall survival during the follow-up. Further, we showed that complete p53 inactivation alone led to neither blast transformation nor HU resistance. Altogether, we revealed patient's age as the strongest factor affecting low-burden TP53 mutation incidence in MPN and found no significant age-independent association between TP53 mutations and hydroxyurea. Mutations may persist at low levels for years without an immediate risk of progression.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a alely $7 D000483

650    _2

$a progrese nemoci $7 D018450

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a frekvence genu $x účinky léků $x genetika $7 D005787

650    _2

$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014

650    _2

$a lidé $7 D006801

650    _2

$a hydroxymočovina $x aplikace a dávkování $7 D006918

650    _2

$a Janus kinasa 2 $x genetika $7 D053614

650    _2

$a akutní myeloidní leukemie $x farmakoterapie $x genetika $7 D015470

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a mutace $x účinky léků $x genetika $7 D009154

650    _2

$a myeloproliferativní poruchy $x farmakoterapie $x genetika $7 D009196

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a nádorový supresorový protein p53 $x genetika $7 D016159

650    _2

$a mladý dospělý $7 D055815

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Pavlova, S $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Malcikova, J $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Kabathova, J $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic.

700    1_

$a Radova, L $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Tom, N $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Tichý, Boris $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 xx0312236

700    1_

$a Plevova, K $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Kantorova, B $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Fiedorova, K $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Slavikova, M $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Bystrý, Vojtěch $7 xx0238315 $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Kissova, J $u Department of Clinical Hematology, Faculty of Medicine, Masaryk University Brno, Czech Republic.

700    1_

$a Gisslinger, B $u Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Austria.

700    1_

$a Gisslinger, H $u Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Austria.

700    1_

$a Penka, M $u Department of Clinical Hematology, Faculty of Medicine, Masaryk University Brno, Czech Republic.

700    1_

$a Mayer, J $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Kralovics, R $u CeMM Research Center for Molecular Medicine of Austrian Academy of Sciences, Vienna, Austria.

700    1_

$a Pospisilova, S $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

700    1_

$a Doubek, M $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine, Masaryk University Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

773    0_

$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 32, č. 2 (2018), s. 450-461

856    41

$u https://pubmed.ncbi.nlm.nih.gov/28744014 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20190405 $b ABA008

991    __

$a 20240117091005 $b ABA008

999    __

$a ok $b bmc $g 1392425 $s 1051420

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2018 $b 32 $c 2 $d 450-461 $e 20170724 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138

GRA    __

$a NV16-29447A $p MZ0

LZP    __

$a Pubmed-20190405